<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104258">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01981161</url>
  </required_header>
  <id_info>
    <org_study_id>1235207</org_study_id>
    <nct_id>NCT01981161</nct_id>
  </id_info>
  <brief_title>Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis</brief_title>
  <acronym>BEST-MS</acronym>
  <official_title>Essai de Phase IV, Multicentrique, Ouvert, Visant à Tester la différence d'efficacité du Natalizumab, Versus le Fingolimod, 2 médicaments Ayant Une AMM Pour le Traitement de la sclérose en Plaques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Under the escalation treatment strategy when a patient displays breakthrough disease
      parameters under first line therapy, MS physicians are allowed by the EMEA to switch for
      Natalizumab ( NTZ) or  fingolimod (FGL). NTZ and FGL efficacy have been demonstrated by
      randomized therapeutic trial. As both treatments have been tested versus placebo a common
      way to compare them is to look at their respective annualized relapse risk ratio decrease.
      Roughly NTZ decrease by 70% and FGL by 50%. Nevertheless it is a terrible comparison since
      the placebo group had different behaviour in the 2 trials and the patients demographic
      features at baseline are also different. Therefore, it is right now totally impossible to
      compare these 2 drugs with a decent methodology. Only a head to head comparison could do it.
      Unfortunately this head-to-head comparison is not available and will not probably be done
      under the drug companies initiative. During the time of this study we will perform a phase
      IV, observational, prospective head to head comparison of NTZ versus FGL efficacy in 600
      patients. Our primary end point will be disease free patients after 1 year of treatment.
      Further, this trial will allow us to collect new biological samples, useful for a validation
      our project main aim. Further these new samples will be obtained from 3 European countries,
      which is a must if we want to generalize our conclusion obtained from a French cohort.
      Cooperation at the European level is thus essential for the implementation of this project .
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Disease free patients</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>comparing the efficacy of Natalizumab with that of Fingolimod with regard to the annual incidence rate (comparison against the annual incidence rate criterion after 1 year</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Fingolimod</arm_group_label>
    <description>patients treated by Fingolimod</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Natalizumab</arm_group_label>
    <description>patients treated by Natalizumab</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      urine and blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Multiple sclerosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients aged between 18 and 55;

          2. diagnosis of relapsing-remitting MS in line with McDonald criteria;

          3. patient needing to be treated with FGL or NTZ, either:

               -  Patients who have not responded to complete and well-conducted treatment with
                  beta interferon. The patients should have presented at least one relapse during
                  the course of the previous year while they were receiving treatment, and should
                  present at least 9 hyper-intense lesions within T2 on a cerebral MRI, or at
                  least 1 enhancing lesion following injection of Gadolinium; or

               -  Patients presenting severe and rapidly developing relapsing-remitting multiple
                  sclerosis, defined by 2 debilitating relapses or more during the course of one
                  year, combined with 1 or more high-intensity lesion(s) following injection of
                  Gadolinium on a cerebral MRI, or a significant increase in lesion load within T2
                  compared to a recent prior MRI.

          4. EDSS score between 0 and 6, not inclusive;

          5. patient who has given his/her free and informed consent, and signed the consent form;

          6. patient who is a member or beneficiary of a sickness insurance scheme;

          7. patient available for 12-month follow-up.

        Exclusion Criteria:

          1. General exclusion criteria: The patient is subject to judicial protection,
             supervision or guardianship, the patient is pregnant, is about to give birth, or is
             breast-feeding, or there is an existing medical or major psychiatric condition that,
             in the investigator's opinion, could represent a risk for the subject or could
             compromise compliance with the study protocol.

          2. Contraindication to the use of NTZ and FGL in line with the marketing authorisation:
             for NTZ, the risk of tuberculosis assessed by means of intracutaneous reaction or
             quantiferon dosage, for FGL, positive VZV serology and an absence of risk factors for
             bradycardia and heart rate problems, and for both molecules, an absence of biological
             signs suggesting immunodepression (negative HIV serology, normal CD3, CD4, CD8 and
             CD19 levels, weight-adjusted dosage of immunoglobulin normal).

          3. prior treatment with FGL or NTZ;

          4. prior treatment with Mitoxantrone or Cyclophosphamide type immunosuppressants during
             the 5 years before inclusion.

             -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Brassat, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>U H Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Brassat, MD, PHD</last_name>
    <phone>33 561 77 20 67</phone>
    <email>brassat.d@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Delphine VERNET</last_name>
    <phone>0561777216</phone>
    <email>vernet.d@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Berger, MD</last_name>
      <email>lrumbach@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Berger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33 000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno Brochet, MD PHD</last_name>
      <email>bruno.brochet@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>bruno brochet, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilles-Louis Defer, MD PHD</last_name>
      <email>defer-gi@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles-Louis Defer, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Vermersch, MD PHD</last_name>
    </contact>
    <investigator>
      <last_name>Patrick Vermersch, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Pelletier, MD PHD</last_name>
    </contact>
    <investigator>
      <last_name>Jean Pelletier, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Debouverie, MD PHD</last_name>
    </contact>
    <investigator>
      <last_name>Marc Debouverie, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Laplaud, MD</last_name>
      <email>david.laplaud@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>David Laplaud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Pasteur</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Lebrun-Frenay, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christine Lebrun-Frenay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier-Nîmes</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Labauge, MD PHD</last_name>
    </contact>
    <investigator>
      <last_name>Labauge Pierre, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jérôme De Seze, MD pHD</last_name>
    </contact>
    <investigator>
      <last_name>Jerome De Seze, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Université de Muenter</name>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>H Wiendl, MD PHD</last_name>
    </contact>
    <investigator>
      <last_name>H Wiendl, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Vall D'Hebron</name>
      <address>
        <city>Barcelone</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xavier Montalban, MD PHD</last_name>
    </contact>
    <investigator>
      <last_name>XAVIER Montalban, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 16, 2013</lastchanged_date>
  <firstreceived_date>November 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>progressive multifocal leucoencephalopathy</keyword>
  <keyword>JC virus</keyword>
  <keyword>Zoster infection</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fingolimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
